RedHill Biopharma

CompanyIsrael

RedHill Biopharma develops one asset, in phase 2 (Opaganib in cholangiocarcinoma). Mostly small molecule acting on SPHK2; based in Israel.

1
Asset
Furthest stage
Phase 2
Raised
$128M
3
Trials
2
Signals

Pipeline

1
  • Opaganib

    Inhibits sphingosine kinase 2, disrupting sphingolipid signaling and promoting cancer cell apoptosis.

    Phase 2, Small molecule, SPHK2, cholangiocarcinoma, cholangiocarcinoma non resectable

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials3
  • Funding rounds and grants7
  • People12
  • Signals4
  • Similar companies6

Intelligence